Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (5963)	11/15/2001 4:19:56 PM
From: TREND1	Respond to of 99280

Zeev I can hope, but will react to what the market does.(g) Larry Dudash

To: Zeev Hed who wrote (5963)	11/15/2001 4:20:00 PM
From: Sam	Respond to of 99280

3:37PM Celera Genomics (CRA) 28.09 +2.04 (+7.8%): Stock trading up 8% on midday note from Banc of America: Axys merger a major positive for CRA (should close tomorrow), makes CRA look more like an integrated biopharma. Merger very complementary: Axys has several advanced preclinical project, CRA has money, exposure, and instrumentation. Most promising N-T drug in Axys pipeline is osteoporosis drug that is partnered with MRK (royalty rate high single digits). CRA holding analyst day on Dec 12. [Maybe CRA will actually make some money one of these days.--Sam]